

From: remonda.gergis@huahaipharmus.com
Sent: Wednesday, November 20, 2019 4:03 AM
To: 'Moore, Maggie' <Maggie.moore@STERICYCLE.com>
Cc: 'Hai Wang' <hai.wang@solcohealthcare.com>; 'David Ayres' <david.ayres@solcohealthcare.com>
Subject: FW: 2768 Valsartan/8282 Irbesartan - Destruction Schedule

Per FDA, please move forward. See below
Thanks,
Remonda

From: ORA PHARM1 RECALLS <orapharm1recalls@fda.hhs.gov>
Sent: Wednesday, November 20, 2019 9:15 AM
To: remonda.gergis@huahaipharmus.com; ORA PHARM1 RECALLS <orapharm1recalls@fda.hhs.gov>
Subject: RE: 2768 Valsartan/8282 Irbesartan - Destruction Schedule

Hello Remonda,

Please move forward.

Please be sure to provide destruction information and a close out report once the action is completed.

Thank you for your patience.

Regards

Lisa Mathew
Recall Coordinator

Division of Pharmaceutical Quality Operations I
Office of Regulatory Affairs
U.S. Food and Drug Administration
T: 973-331-4917
F: 973-331-4969

Division of Pharmaceutical Quality Operations I: CT; DC; DE; MA; MD; ME; NH; NJ; NY; PA; RI; VA; VT; WV

orapharm1recalls@fda.hhs.gov

